Dihexa vs P21
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small synthetic peptide built from angiotensin IV, engineered at Washington State University to be orally active and to cross into the brain. The pitch is bold: it is studied as a procognitive compound that may rebuild synaptic connections, and lab claims of extreme potency made it a darling of the nootropic underground. The reality check: every supporting study is in cells or rodents, there are zero human clinical trials, and a foundational 2012 biochemistry paper describing its target was later retracted.
Also: P021, Ac-DGGLAG-NH2
P21 (also written P021) is a small synthetic peptide reverse-engineered from the most active region of ciliary neurotrophic factor (CNTF), with an adamantane group bolted on to help it survive in the body and reach the brain. It is studied as a neurogenic and neurotrophic compound for Alzheimer's disease and other memory disorders, with the appeal of getting CNTF-like benefits in a small, orally available molecule. The honest status: it looks genuinely promising in mouse models, but the entire evidence base comes from a single research group and there are no human trials.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Dihexa | P21 |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Dihexa is derived from angiotensin IV, a fragment of the renin-angiotensin system that has long been linked to memory in animal work. The leading hypothesis is that it acts on the hepatocyte growth factor (HGF) and its receptor c-Met, a growth-factor system that drives the formation of new dendritic spines and synapses. In cultured hippocampal neurons, dihexa and related angiotensin IV analogs increase spine density, and that effect disappears when the HGF/c-Met system is blocked, which is the main evidence the pathway matters. It is worth being blunt that the exact molecular interaction has been contested, since the original paper proposing direct HGF binding was retracted, so the mechanism is best treated as a working hypothesis rather than settled fact. | P21 is a peptidergic CNTF mimetic, meaning it was designed to copy the active part of the natural neurotrophic factor CNTF without the downsides of the full protein. In rodent studies it boosts neurogenesis in the dentate gyrus of the hippocampus and raises brain-derived neurotrophic factor (BDNF), apparently by inhibiting leukemia inhibitory factor (LIF) signaling. Higher BDNF in turn dampens the activity of GSK-3 beta, a major enzyme that drives abnormal tau phosphorylation, which is the proposed link to reduced Alzheimer-type pathology. These are real findings in animals, but the framing of P21 as a clean single-pathway BDNF booster is a simplification of a still-incomplete picture. |
| Common Dosing | 5-20 mg oral or sublingual daily Once daily, effects can last up to 10 days | Limited community data available See research protocols |
| Administration | Oral, sublingual, or intranasal | Oral (nasal in some studies) |
| Typical Duration | Cycles of 2-4 weeks | Ongoing supplementation in studies |
| Best Time to Take | Morning | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The published evidence on dihexa is entirely preclinical. Harding, McCoy and colleagues at Washington State University reported that metabolically stabilized angiotensin IV analogs, including dihexa, restored cognition in scopolamine-impaired and aged rats and stimulated synaptogenesis in cultured neurons (J Pharmacol Exp Ther, 2012 and follow-ups). A 2014 study tied the procognitive and synaptogenic effects of these analogs to the HGF/c-Met system. There are no registered human clinical trials and no published human safety or pharmacokinetic data, so dosing, long-term safety and whether any of the rodent benefit translates to people are all unknown. One important caveat for anyone reading the primary literature: the 2012 paper that first proposed dihexa as an HGF/Met modifier was formally retracted in 2024, which weakens the strongest mechanistic claim. Treat dihexa as an interesting research molecule with promising animal data and a notable evidence gap, not as a proven cognitive enhancer. | The research record on P21 is preclinical and concentrated in the work of Iqbal, Kazim and colleagues. In a 3xTg triple-transgenic mouse model of Alzheimer's disease, chronic oral P021 reduced tau hyperphosphorylation, increased BDNF, enhanced neurogenesis and improved memory performance (J Alzheimers Dis, 2014). Later work in the same line showed P021 prevented dendritic and synaptic deficits and cognitive impairment in animal models, and related studies extended it to Down syndrome and CDKL5 deficiency mouse models. The consistent thread is that across multiple rodent disease models the compound improves synaptic and cognitive measures with a favorable tolerability profile in those animals. The major limitation is that there are no published human clinical trials, no human safety data, and the evidence comes largely from one collaborating group, so independent replication and any translation to people remain open questions. |
Frequently Asked Questions: Dihexa vs P21
What is the difference between Dihexa and P21?
Dihexa is a cognitive peptide that dihexa (n-hexanoic-tyr-ile-(6) aminohexanoic amide) is a small synthetic peptide built from angiotensin iv, engineered at washington state university to be orally active and to cross into the brain. the pitch is bold: it is studied as a procognitive compound that may rebuild synaptic connections, and lab claims of extreme potency made it a darling of the nootropic underground. the reality check: every supporting study is in cells or rodents, there are zero human clinical trials, and a foundational 2012 biochemistry paper describing its target was later retracted. P21 is a cognitive peptide that p21 (also written p021) is a small synthetic peptide reverse-engineered from the most active region of ciliary neurotrophic factor (cntf), with an adamantane group bolted on to help it survive in the body and reach the brain. it is studied as a neurogenic and neurotrophic compound for alzheimer's disease and other memory disorders, with the appeal of getting cntf-like benefits in a small, orally available molecule. the honest status: it looks genuinely promising in mouse models, but the entire evidence base comes from a single research group and there are no human trials. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Dihexa or P21?
Neither is universally "better" - the choice depends on your specific goals. Dihexa is typically used for cognitive purposes, while P21 is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Dihexa and P21 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Dihexa and P21 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.